Pegenzileukin is under clinical development by Sanofi and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pegenzileukin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SAR-444245 (THOR-707) is under development for the treatment of solid tumors including melanoma, metastatic melanoma, classic Hodgkin lymphoma (cHL), non-small cell lung cancer, thoracic cancer, skin cancer, head and neck squamous cell carcinoma, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, oral cavity (mouth) cancer, malignant pleural mesothelioma, cutaneous squamous cell carcinoma (CSCC), esophageal squamous cell carcinoma (ESCC), advanced unresectable or metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic hepatocellular carcinoma (HCC), metastatic colorectal cancer and diffuse large B-cell lymphoma. The drug candidate is an improved version of interleukin-2. It is based on synthorx platform technology. It is administered by intravenous route.
Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals and supplements. Sanofi‘s R&D efforts focus on advancing a combination drugs to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa and the Middle East. Sanofi is headquartered in Paris, France.
For a complete picture of Pegenzileukin’s drug-specific PTSR and LoA scores, buy the report here.